Evolent Health (EVH) Cash & Equivalents (2015 - 2026)

Evolent Health's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $142.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 42.4% year-over-year to $142.0 million in Q1 2026; TTM through Mar 2026 was $142.0 million, a 42.4% decrease from a year earlier, with the FY2025 full-year figure at $151.9 million, up 45.73% from the prior year.
• Cash & Equivalents slipped to $142.0 million in Q1 2026 per EVH's latest filing, from $151.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $246.5 million in Q1 2025 and bottomed at $96.6 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $156.8 million (2022), against an average of $158.9 million.
• Across the five-year window, Cash & Equivalents tumbled 47.66% in 2024 and jumped 49.29% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $188.2 million in 2022, then climbed by 2.46% to $192.8 million in 2023, then sank by 45.96% to $104.2 million in 2024, then surged by 45.73% to $151.9 million in 2025, then slipped by 6.49% to $142.0 million in 2026.
• Per Business Quant, the three latest EVH Cash & Equivalents figures stand at $142.0 million (Q1 2026), $151.9 million (Q4 2025), and $116.7 million (Q3 2025).